Medivir to present at the Redeye Fight Cancer Day

Rhea-AI Summary

Medivir AB (Nasdaq Stockholm: MVIR) announced its participation in the Redeye Fight Cancer Day on January 19, 2023. CEO Jens Lindberg will present the ongoing clinical study of fostroxacitabine bralpamide (fostrox) at 13.35 CET. The presentation will be broadcast live and can be accessed through the event page. Additionally, it will be available later on Medivir's website. Medivir focuses on developing innovative cancer treatments for unmet medical needs, particularly targeting liver cancer. The company’s drug fostrox aims to minimize side effects while effectively treating cancer cells. Medivir's shares are listed under the ticker MVIR.

STOCKHOLM, Jan. 16, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day on January 19, 2023.

CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 13.35 CET.

The presentation is live broadcasted and can be followed at the event page;
https://www.redeye.se/events/868559/redeye-theme-fight-cancer

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

https://mb.cision.com/Main/652/3698000/1781446.pdf

Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-redeye-fight-cancer-day-301722224.html

SOURCE Medivir

FAQ

When is Medivir's presentation at the Redeye Fight Cancer Day?

Medivir's presentation at the Redeye Fight Cancer Day is scheduled for January 19, 2023, at 13.35 CET.

What is fostroxacitabine bralpamide?

Fostroxacitabine bralpamide (fostrox) is a pro-drug developed by Medivir designed to selectively treat liver cancer cells while minimizing side effects.

Who is presenting for Medivir at the Redeye event?

CEO Jens Lindberg will present Medivir's clinical study at the Redeye Fight Cancer Day.

Where can I watch Medivir's presentation?

The presentation can be watched live on the event page and will also be available later on Medivir's website.

What is the stock symbol for Medivir?

Medivir's stock is listed under the ticker MVIR on Nasdaq Stockholm.

Which company is collaborating with Medivir for the drug Birinapant?

Medivir has outlicensed Birinapant to IGM Biosciences (Nasdaq: IGMS) for development in combination with IGM-antibodies.